GSK HLN 藥 英

GSK says it disagrees with California state court ruling on Zantac

GSK表示，不同意加州州法院就Zantac做出的裁決

Published: March 24, 2023 at 6:13 a.m. ET
By Steve Goldstein

U.K. pharmaceutical giant GSK on Friday said it disagreed with a California state court ruling on Zantac, or ranitidine, and its links with cancer. "Following the 13 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer," the pharmaceutical said. It added the decision relates only to the question of whether the plaintiff's experts can testify at trial. "It does not mean that the Court agrees with plaintiff's experts' scientific conclusions or their litigation-driven science," the company said. GSK GSK, -3.83% shares fell 4% in London.

英國製藥巨頭GSK於週五表示，對於加州州法院就Zantac或者Ranitidine和癌症之間的聯繫做出的裁決不同意見。該製藥公司表示："在對Ranitidine使用的人類數據進行的13項流行病學研究後，科學共識是沒有一致或可靠的證據表明Ranitidine增加了任何癌症的風險。"它還補充說，這一決定僅涉及原告專家能否在審判中作證的問題。"這並不意味著法院同意原告專家的科學結論或他們訴訟驅動的科學,"該公司說。 GSK的股票在倫敦下跌了4%。

GSK sells $1 bln discounted stake in spin-off Haleon

May 11 (Reuters) - British drugmaker GSK (GSK.L) on Friday sold 240 million shares in its consumer healthcare business Haleon (HLN.L) at 335 pence per share, raising about 804 million pounds ($1 billion), the company said.

Haleon, the world's biggest standalone consumer health company, comprising assets from GSK and Pfizer (PFE.N), sells non-prescription drugs, vitamins and oral care products.

The sale price represents a 2.3% discount to Haleon's closing price of 342.85 pence on Thursday and lowers the stake of GSK, the second-largest shareholder, to 10.3%.

2023年5月11日（路透社）- 英國製藥公司GSK（GSK.L）於週五以每股335便士的價格出售其消費者保健業務Haleon（HLN.L）的2.4億股股份，籌集了約8.04億英鎊（10億美元），該公司表示。

Haleon是全球最大的獨立消費者健康公司，由GSK和輝瑞（PFE.N）的資產組成，銷售非處方藥品、維生素和口腔護理產品。

出售價格較前一日的Haleon收盤價342.85便士折價2.3％，並將GSK的持股比例降至10.3％，成為第二大股東。

GSK raises full-year profit forecast, says first-half will see stronger sales

May 1 (Reuters) - GSK (GSK.L), opens new tab raised its full-year profit forecast on Wednesday and said its sales would be higher in the first six months of the year than the second half on the back of strong demand for its common respiratory virus and shingles vaccines.
The London-listed drugmaker said it now expects a rise of 8% to 10% in annual adjusted earnings per share, up from the 6%-9% growth previously forecast. It also expects its 2024 sales to rise in the upper end of its 5% to 7% forecast range.

CEO Emma Walmsley's strategy has been centred around sharpening GSK's focus on vaccines and infectious diseases, and shifting its HIV focus to long-acting treatment and prevention therapies. The strategy has paid off as the company gears up for 12 new launches from 2025.
The British drugmaker reported a profit of 43.1 pence per share on sales of 7.36 billion pounds ($9.18 billion) for the first quarter, above analysts' average expectations of a 37.3 pence profit on sales of 7.07 billion pounds, according to a company-compiled consensus.

ChatGPT：
葛蘭素史克（GSK）提高了全年盈利預測，表示上半年銷售將會較強

倫敦（路透社訊） - 5月1日，葛蘭素史克（GSK.L）提高了其全年盈利預測，並表示由於對其常見呼吸道病毒和帶狀疱疹疫苗的強烈需求，今年上半年的銷售將會高於下半年。這家在倫敦上市的藥品製造商表示，預計年度調整後每股盈利將增長8%至10%，較之前預測的6%-9%增長有所提高。它還預計，2024年的銷售額將在5%至7%的預測範圍上限提高。

首席執行官艾瑪·沃爾姆斯利（Emma Walmsley）的戰略圍繞著強化葛蘭素史克對疫苗和傳染病的關注，並將其對艾滋病病毒的關注轉向長效治療和預防療法。該戰略已經取得了成功，因為公司正準備從2025年推出12個新產品。根據公司編制的共識，這家英國藥品製造商第一季度每股盈利為43.1便士，銷售額為73.6億英鎊（91.8億美元），高於分析師對每股盈利37.3便士，銷售額為70.7億英鎊的平均預期。